Financial BurdenPartnered development for phentolamine ophthalmic solution funded by strategic partner Viatris is expected to draw data attention in presbyopia and dim light vision disturbances after keratorefractive surgery.
Increased ExpendituresFY25E G&A projection is now at $25mn (up from prior estimate of $14mn), which indicates increased expenditures.
Reduced Price TargetFollowing these updates and accounting for recent dilution, DCF-based PT is at $5, down from $8.